Presentation is loading. Please wait.

Presentation is loading. Please wait.

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,

Published by Modified over 6 years ago

Similar presentations

Presentation on theme: "Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,"— Presentation transcript:

1 Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi, Feng Xie, John Marshall, E. Jan Irvine, Kathryn Gaebel, Kaitryn Campbell, Rob Hopkins, Daria O’Reilly, Jean-Eric Tarride, Ron Goeree  Journal of Crohn's and Colitis  Volume 6, Issue 1, Pages (February 2012) DOI: /j.crohns Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

2 Figure 1 Graphical representation of the Crohn's disease model structure and movement between health states after 1st line treatment. Journal of Crohn's and Colitis 2012 6, 77-85DOI: ( /j.crohns ) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

3 Figure 2 Graphical representation of the Crohn's Disease model structure and movement between health states after 2nd line treatment. Journal of Crohn's and Colitis 2012 6, 77-85DOI: ( /j.crohns ) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

4 Figure 3 Cost-effectiveness efficiency frontier for CD model.
Journal of Crohn's and Colitis 2012 6, 77-85DOI: ( /j.crohns ) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

5 Figure 4 Cost-effectiveness acceptability curves.
Journal of Crohn's and Colitis 2012 6, 77-85DOI: ( /j.crohns ) Copyright © 2011 European Crohn's and Colitis Organisation Terms and Conditions

Download ppt "Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease  Gord Blackhouse, Nazila Assasi,"

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages 332-384 (March.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and.

The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and.
How do psychological variables influence coping strategies in inflammatory bowel disease?  Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,

How do psychological variables influence coping strategies in inflammatory bowel disease?  Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,
Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 

Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 
Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.

Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease  Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease  Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.
Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody? 

Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody? 
Concurrent small bowel adenocarcinoma and carcinoid tumor in Crohn's disease — Case report and literature review  Doron Boltin, Zohar Levi, Marisa Halpern,

Concurrent small bowel adenocarcinoma and carcinoid tumor in Crohn's disease — Case report and literature review  Doron Boltin, Zohar Levi, Marisa Halpern,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 
YouTube® and inflammatory bowel disease

YouTube® and inflammatory bowel disease
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,

A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,

Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Ineffectiveness of infliximab therapy in severe infantile Crohn's disease  Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan,

Ineffectiveness of infliximab therapy in severe infantile Crohn's disease  Nuray Uslu, Yusuf Usta, Inci Nur Saltik-Temizel, Hulya Demir, Figen Gürakan,
Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.

Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series  Erik Mooiweer,

Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series  Erik Mooiweer,
Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,

Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,
Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome 

Similar presentations

Ads by Google